Catriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total value of $498,700.00. Following the transaction, the insider now directly owns 95,648 shares of the company’s stock, valued at $4,769,965.76. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Catriona Yale also recently made the following trade(s):

• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The shares were sold at an average price of $29.11, for a total value of $264,144.14.

Akero Therapeutics Stock Performance

NASDAQ:AKRO opened at $51.84 on Friday. The stock has a market cap of $3.62 billion, a P/E ratio of -13.82 and a beta of -0.11. The stock has a 50 day simple moving average of $37.02 and a 200 day simple moving average of $31.73. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40.

Institutional Trading of Akero Therapeutics

Several hedge funds have recently added to or reduced their stakes in AKRO. Wellington Management Group LLP lifted its holdings in Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Akero Therapeutics during the 3rd quarter worth approximately $37,392,000. RTW Investments LP increased its stake in Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock worth $190,840,000 after acquiring an additional 940,388 shares during the period. Deep Track Capital LP increased its stake in Akero Therapeutics by 116.0% during the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock worth $41,452,000 after acquiring an additional 800,216 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in Akero Therapeutics during the 4th quarter worth $18,059,000.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AKRO shares. UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Citigroup raised their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. HC Wainwright raised their price objective on Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $35.00 to $63.00 in a research report on Thursday, January 30th. Finally, Morgan Stanley raised their price objective on Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $75.86.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.